Anna Pluzanska
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Papers in
- Oncology 18
- Cancer Treatment and Pharmacology 7
- Lung Cancer Research Studies 3
- HER2/EGFR in Cancer Research 3
-
- Lung Cancer Treatments and Mutations 9
- Co-authors
- Nicholas David James (1 shared paper)Stéphane Marie. Oudard (1 shared paper)Kim N. Chi (1 shared paper)Jozsef Horti (1 shared paper)Mark Andrew Rosenthal (1 shared paper)Ronald de Wit (1 shared paper)Ingela Turesson (1 shared paper)Christine Théodore (1 shared paper)
- Journals
- Journal of Clinical Oncology (9 papers)Annals of Oncology (5 papers)European Journal of Cancer (4 papers)Lung Cancer (3 papers)British Journal of Cancer (3 papers)
- Partner nations
- PolandGermanyUnited States
In The Last Decade
Anna Pluzanska
52 papers receiving 14.1k citations
Anna Pluzanska's Hit Papers
Peers
Comparison fields: 5 of 130
- Pulmonary and Respiratory Medicine 7.7k
- Oncology 5.9k
- Cancer Research 2.9k
- Genetics 1.5k
- Radiology, Nuclear Medicine and Imaging 1.0k
Countries citing papers authored by Anna Pluzanska
This map shows the geographic impact of Anna Pluzanska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Pluzanska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Pluzanska more than expected).
Fields of papers citing papers by Anna Pluzanska
This network shows the impact of papers produced by Anna Pluzanska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Pluzanska. The network helps show where Anna Pluzanska may publish in the future.
Co-authors
The 25 scholars most cited alongside Anna Pluzanska, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Hit paper breakdown → | 2004 | 4744 |
| 2 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Hit paper breakdown → | 2007 | 1845 |
| 3 | Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 Hit paper breakdown → | 2004 | 1466 |
| 4 | Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group Hit paper breakdown → | 2001 | 849 |
| 5 | Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group Hit paper breakdown → | 2003 | 810 |
| 6 | Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial Hit paper breakdown → | 2007 | 751 |
| 7 | Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival Hit paper breakdown → | 2012 | 680 |
| 8 | Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group Hit paper breakdown → | 2003 | 616 |
| 9 | Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Hit paper breakdown → | 2011 | 521 |
| 10 | 2008 | 352 | |
| 11 | 2000 | 250 | |
| 12 | 2001 | 249 | |
| 13 | 1999 | 225 | |
| 14 | 2000 | 222 | |
| 15 | 2003 | 161 | |
| 16 | 2004 | 128 | |
| 17 | 2008 | 82 | |
| 18 | 2003 | 77 | |
| 19 | 2003 | 71 | |
| 20 | 2003 | 70 |
About Anna Pluzanska
Anna Pluzanska is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine, Pathology and Forensic Medicine and Cancer Research, having authored 54 papers that have together received 14.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Cancer Treatment and Pharmacology (7 papers), Ovarian cancer diagnosis and treatment (4 papers), Lung Cancer Research Studies (3 papers), Estrogen and related hormone effects (3 papers), Toxin Mechanisms and Immunotoxins (3 papers), Breast Cancer Treatment Studies (3 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.7k citations), Oncology (5.9k citations), Cancer Research (2.9k citations), Genetics (1.5k citations) and Radiology, Nuclear Medicine and Imaging (1.0k citations). Anna Pluzanska has collaborated with scholars based in Poland, Germany and United States. Frequent co-authors include Nicholas David James, Stéphane Marie. Oudard, Kim N. Chi, Jozsef Horti, Mark Andrew Rosenthal, Ronald de Wit, Ingela Turesson, Christine Théodore, William R. Berry and Ian F. Tannock. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Lung Cancer and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.